Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10717 clinical trials
Featured trial
Secondary Amenorrhea (Absence of a period)

Secondary Amenorrhea (Absence of a period)

  • 416 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Participants with agitation secondary to dementia of the Alzheimer's type

Participants with agitation secondary to dementia of the Alzheimer's type. Eligible participants for this study must have a diagnosis of probable AD and must have clinically meaningful agitation

mini-mental state examination
dementia
mental state examination
agitation
  • 0 views
  • 29 Jul, 2021
  • 1 location
Featured trial
A study to evaluate preventative secondary stroke treatments.

A study to evaluate preventative secondary stroke treatments.

  • 404 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

  • 204 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

The objectives of this study are to evaluate the safety and efficacy of Zimura intravitreal administration in patients with geographic atrophy secondary to age-related macular degeneration (AMD

  • 0 views
  • 24 Jun, 2021
  • 1 location
Featured trial
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecute inhibitor of KRASG12C. TNO155 is a selective, orally bioavailable allosteric inhibitor of wild type SHP2.

solid tumor
solid tumors
malignant solid tumor
advanced solid tumor
  • 114 views
  • 19 Feb, 2021
  • 10 locations
Featured trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

solid tumor
advanced solid tumor
malignant solid tumor
  • 413 views
  • 08 Jul, 2021
  • 73 locations
Featured trial
  • 614 views
  • 08 Nov, 2020
  • 1 location
Featured trial
  • 76 views
  • 25 Mar, 2021
  • 1 location
Featured trial
Memory Loss Prevention

prevention for those at risk of developing dementia secondary to Alzheimer’s disease even before symptoms occur.Research studies for “memory loss prevention” include those who are at

dementia
alzheimer's disease
  • 11 views
  • 30 Jul, 2021
  • 1 location